Multiple primary cancer in patients with cancer of the head and neck: Second cancer of the head and neck, esophagus, and lung

Licciardello, Jere T.W.; Spitz, Margaret R.; Hong, Waun Ki

doi:10.1016/0360-3016(89)90096-5

Cited by 238 publications

(108 citation statements)

References 32 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…[26] Çalo¤lu et al determined that 27% of 34 patients with larynx cancer who received surgery+RT and 35% of 26 patients under curative RT had experienced recurrences in a median 18 months. [27] Ataman et al observed that 13% of 144 patients with early-stage larynx cancer (Tis, T1 and T2) had recurrences (33,78, and 83% within the first one, two, and three years, respectively). [28] In the RTOG 91-11 study (locally advanced stage, n=547), the authors observed recurrences in patients under induction CT+RT (70/ 173), CT+RT+CRT (34/172), and radiotherapy (80/ 173) and in 32% of all patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Yücel¹

2013

J Med Updates

View full text Add to dashboard Cite

ÖzetAmaç: Bu çal›flmada, klini¤imizde tedavi edilen larinks kanserli hastalar›n tedavi sonuçlar›, tedavilerin yan etkileri ve hastalar›n sa¤kal›-m›n› etkileyen prognostik faktörlerin belirlenmesi amaçlanm›flt›r.Yöntem: Çal›flmada 90 hasta verisi analiz edilmifltir. Hastalar›n performans statüsü 2010'da revize edilmifl Do¤u Onkoloji ‹flbirli¤i Grubu (Eastern Cooperative Oncology Group, ECOG) skorlama sistemine göre de¤erlendirilmifltir. Bulgular:Hastalar›n %97'si erkek ve %3'ü kad›n olup, medyan yafl› 59 (37-86) idi. Erken evre %43, lokal ileri evre %55, metastatik evre kanser %2 hastada saptand›. Hastalar›n %53'ünü glottik kanserler, %47'sini supraglottik kanserler oluflturmaktayd›. Supraglottik kanserlerin performans durumu (p=0.022), grade (p=0.033), T evresi (p=0.034), lenf nod metastaz› (p=0.001), hastal›k evresi (p=0.007) bak›m›ndan glottik kanserlere göre daha kötü özelliklere sahip oldu¤u saptand›. Medyan 15 (da¤›l›m: 5-96) ayda hastalar›n %17'sinde nüks, medyan 17 (da¤›l›m: 1-155) ayda da hastalar›n %12'sinde uzak metastaz tespit edildi. Hastalar›n sa¤kal›m›n› komorbidite (p=0.032), performans durumu (p=0.022), hemoglobin düzeyi (p=0.003), T evresi (p=0.006), hastal›k evresi (p=0.011), kilo kayb› (p=0.002) etkilemekteydi. Kemoradyoterapi uygulanan hastalarda mukozit (p<0.001), bulant› kusma (p<0.001), kilo kayb› (p=0.005), nötropeni (p=0.001) ve anemi (p=0.003), radyoterapi uygulanan hastalara göre daha fazla gözlenmifltir.Sonuç: Hemoglobin düzeyi, T evresi, komorbidite ve kilo kayb› bu hastalar için ba¤›ms›z prognostik faktörler olmufltur.Anahtar sözcükler: Larinks kanseri, sa¤kal›m, prognoz, yan etki. AbstractObjective: Our aim was to determine the treatment results, side effects and the prognostic factors affecting survival in patients with larynx cancer treated in our clinic. Methods:Data of a total of 90 patients with larynx carcinoma were included in the study. The patients' performance scores were evaluated according to the Eastern Cooperative Oncology Group (ECOG) system.Results: Eighty-seven (97%) patients were male and three patients (3%) were female. The median age of the patients was 59 (37-86) years. Early-stage, locally advanced stage, and metastatic disease were detected in 43, 55, and 2% of the patients, respectively. Laryngeal cancers were observed in the glottic (53%), and supraglottic (47%) regions. Performance score (p=0.022), grade (p=0.033), lymph node metastasis (p=0.001), T stage (p=0.034) and disease stage (p=0.007) were significantly unfavourable in supraglottic cancers compared to glottic cancers. Recurrence was observed in 17% of the patients in a median 15 (range: 5-96) months. Distant metastasis was observed in 12% of the patients in a median 17 (range: 1-155) months. The factors affecting survival were the presence of comorbidities (p=0.032), performance status (p=0.022), hemoglobin level (p=0.003), T stage (p=0.006), disease stage (p=0.011), and weight loss (p=0.002). When RT-and CRT-associated side effects were compared, the incidence of adverse effects such as mucositis ...

show abstract

Section: Discussionmentioning

confidence: 99%

“…[32,33] According to the literature, the incidence of second primary malignancy in larynx cancers ranges between 11-29%. [34][35][36] In a populationbased study performed between 1986-2008, Liao et al determined that 9,996 patients out of 93,891 patients with head neck cancer (11%) had second primary malignancies.…”

Section: Discussionmentioning

confidence: 99%

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Yücel¹

2013

J Med Updates

View full text Add to dashboard Cite

show abstract

“…The prevalence of a second SCC in cadaver dissection studies ranges between 3.7% and 15.5% [3,4]. For the highest-risk subgroups metachronous SCC occur in about 4% of patients per year [5]. Panendoscopy studies have shown the prevalence of synchronous primary SCC to range from 1.4 to 17% [6].…”

Section: Introductionmentioning

confidence: 99%

Head and neck squamous cell carcinoma (HNSCC) – detection of synchronous primaries with 18F-FDG-PET/CT

Strobel

Haerle

Stoeckli

et al. 2009

Eur J Nucl Med Mol Imaging

117

View full text Add to dashboard Cite

Purpose The aim of the study was to evaluate 18 F-FDG-PET/CT for the detection of synchronous primaries at initial staging of patients with head and neck squamous cell carcinoma (HNSCC). Methods FDG-PET/CT images acquired between March 2001 and October 2007 in 589 consecutive patients (147 women, 442 men; mean age 61.5 years, age range 32-97 years) with proven HNSCC were reviewed for the presence of synchronous primaries. Cytology, histology and/or clinical and imaging follow-up served as reference standard.Results FDG-PET/CT showed 69 suspected synchronous primaries in 62 patients of which 56 were finally confirmed in 44 patients. Of the 56 second cancers, 46 (82%) were found in the aerodigestive tract in the following locations: lung (26, 46%), head and neck (15, 17%), oesophagus (5, 9%). Ten second cancers (18%) were located outside the aerodigestive tract (colon, five; stomach, lymphoma, breast, thymus and kidney, one each). Six patients had three synchronous primaries and three patients had four synchronous cancers. Nine synchronous cancers were not detected by PET/CT (four head and neck, two lung, two oesophageal, one gastric). False-positive PET/CT findings were mainly related to benign FDG uptake in the intestine due to benign or precancerous polyps or physiological FDG uptake in other head and neck regions. Overall the prevalence of synchronous second primaries according to the reference standard was 9.5%, of which 84% were detected with FDG-PET/CT. In 80% of the patients, therapy was changed because of the detection of a synchronous primary. Conclusion FDG-PET/CT detects a considerable number of synchronous primaries (8.0% prevalence) at initial staging of patients with HNSCC. Synchronous cancers were predominantly located in the aerodigestive tract, primarily in the lung, head and neck and oesophagus. Detection of second primaries has an important impact on therapy. PET/ CT should be performed before panendoscopy.

show abstract

“…Oral cancer progresses from hyperplastic lesions, through dysplasia and carcinoma in situ to invasive carcinoma [9][10][11]. Patients with oral cancers have an increased incidence of second primary tumors of the oral cavity [12] [13]. Although patients with early lesions have a high cure rate of their primary tumors; continued exposure to carcinogenic insult (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…Although patients with early lesions have a high cure rate of their primary tumors; continued exposure to carcinogenic insult (e.g. tobacco and alcohol) and potential promoters will accelerate the development of a second primary [13,14]. Currently, oral cancer is generally treated with surgery although there has been some success with retinoids [15].…”

Section: Introductionmentioning

confidence: 99%

Effects of 1,4-phenylenebis(methylene)selenocyanate on mutagenesis and p53 protein expression in the tongue of lacI rats treated with 4-nitroquinoline-N-oxide

Guttenplan

Chen

Khmelnitsky

et al. 2007

Mutation Research/Genetic Toxicology and Environmental Mutagene

View full text Add to dashboard Cite

Previously we showed that the organoselenium compound, 1,4-phenylenebis(methylene) selenocyanate (p-XSC)1 inhibits 4-nitroquinoline-N-oxide (4-NQO)-induced tongue tumorigenesis in Fisher rats. Here we investigate possible mechanisms of this inhibition by monitoring mutagenesis and p53 protein levels in lacI and conventional Fisher rats treated with: 1) a carcinogenic dose of 4-NQO for 10 weeks in drinking water, 2) 4-NQO + p-XSC (15 ppm as selenium), and 3) 4-NQO followed by p-XSC. For mutagenesis studies, rats were euthanized at 7, 12 or 23 wks after the start of 4-NQO. For studies on p53 levels, rats were euthanized at 11, 15 and 23 wks. Appropriate controls were also monitored. In the 4-NQO-alone groups, the mutant fraction (MF) in the cII gene in tongue increased at least 50 × background level. The MF (in units of mutants/10 5 plaque forming units) for the 7, 12 and 23 week 4-NQO groups were respectively, 184 ± 88, 237 ± 105, 329 ± 110. Thus, mutagenesis increased with length of exposure and post-treatment time. p-XSC modestly (ca. 15 -30%) inhibited mutagenesis under all conditions. The inhibition reached significance at the last time point. When p-XSC was administered after 4-NQO, the MF was also modestly reduced. In 4-NQOalone animals, levels of p53 in tongue (determined by Western blotting) were 1, 1.5 and 2.4 control levels at 10, 15 and 23 weeks respectively. In the p-XSC + 4-NQO group, the enhancement in p53 levels by 4-NQO treatment was decreased about 90% at 15 weeks and 45% (P < 0.05) at 23 weeks, and by slightly smaller percentages in corresponding post-treatment groups. p-XSC alone did not alter p53 levels. As p53 levels generally increase in response to DNA damage, these results suggest that p-XSC reduces 4-NQO-induced DNA damage, resulting in reduced 4-NQO-induced mutagenesis and carcinogenesis. However, the fact that p-XSC is also effective when administered after 4-NQO, suggests additional mechanisms of inhibition exist.

show abstract

Multiple primary cancer in patients with cancer of the head and neck: Second cancer of the head and neck, esophagus, and lung

Cited by 238 publications

References 32 publications

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Treatment results, side effects and prognostic factors affecting survival in patients with larynx cancer

Head and neck squamous cell carcinoma (HNSCC) – detection of synchronous primaries with 18F-FDG-PET/CT

Effects of 1,4-phenylenebis(methylene)selenocyanate on mutagenesis and p53 protein expression in the tongue of lacI rats treated with 4-nitroquinoline-N-oxide

Contact Info

Product

Resources

About